Cladribine and cytarabine in refractory multisystem Langerhans cell histiocytosis: results of an international phase 2 study

Donadieu, Jean; Bernard, Frédéric; M. van Noesel, Max; Barkaoui, Mohamed; Bardet, Odile; Mura, Rosamaria; Aricò, Maurizio; Piguet, Christophe; Gandemer, Virginie; Armari Alla, Corinne; Clausen, Niels; Jeziorski, Éric; Lambilliote, Anne; Weitzman, Sheila; Henter, Jan‐Inge; van den Bos, Cor; Salvage Group of the Histiocyte Society, the

doi:10.1182/blood-2015-03-635151

Public

Cladribine and cytarabine in refractory multisystem Langerhans cell histiocytosis: results of an international phase 2 study

Shared by NobleBlocks on Jul 20, 2015 • 12:00 AM UTC

Authors:

Jean Donadieu

Frédéric Bernard

Max M. van Noesel

Abstract

An international phase 2 study combining cladribine and cytarabine (Ara-C) was initiated for patients with refractory, risk-organ-positive Langerhans cell histiocytosis (LCH) in 2005. The protocol, comprising at least two 5-day courses of Ara-C (1 g/m(2) per day) plus cladribine (9 mg/m(2) per day) ...

Subject

Cladribine

Medicine

Cytarabine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!